HIGH CONCENTRATION INSULIN FORMULATION

    公开(公告)号:US20220249619A1

    公开(公告)日:2022-08-11

    申请号:US17626025

    申请日:2020-07-10

    申请人: Novo Nordisk A/S

    摘要: The invention concerns a soluble insulin preparation comprising NϵB29-hexadecandioyl-γ-Glu-(desB30) human insulin in a concentration from 1800 nmol/ml to 4200 nmol/ml, Zinc ions in a concentration from 4.0 Zn/6Ins to 7.0 Zn/6Ins, Niacinamide in a concentration from 110 mM to 220 mM or treprostinil in a concentration from 0.02 μg/ml to 1 μg/ml, Citrate in a concentration from 6 mM to 40 mM, and pH in the range from 7.0 to 8.0. The invention further comprises a method for using the soluble insulin preparation for reducing the blood glucose level in a mammal and a process for preparing the soluble insulin preparations.

    Drug Filled Delivery Assembly
    10.
    发明申请
    Drug Filled Delivery Assembly 有权
    药品交付装配

    公开(公告)号:US20140336586A1

    公开(公告)日:2014-11-13

    申请号:US14361527

    申请日:2012-11-30

    申请人: Novo Nordisk A/S

    IPC分类号: A61M5/24

    摘要: A drug delivery assembly comprises a housing (110), a piston (120) axially displaceable in the housing, and a variable volume reservoir (105) formed by the housing and the piston and containing a fluid first drug. The assembly further comprises an exterior fluid inlet (150) arranged in or configured to be arranged in fluid communication with the reservoir, a fluid outlet (145) arranged in or configured to be arranged in fluid communication with the reservoir, biasing means (130) configured for moving the piston forwards, and releasable retaining means (113) configured for retaining the piston in an initial position, whereby the biasing means is allowed to move the piston forwards to expel fluid drug from the reservoir when the retaining means is released.

    摘要翻译: 药物递送组件包括壳体(110),在壳体中可轴向移动的活塞(120)和由壳体和活塞形成并容纳流体第一药物的可变容积储存器(105)。 该组件还包括布置在或配置为与储存器流体连通的外部流体入口(150),布置在或配置成与储存器流体连通的流体出口(145),偏置装置(130) 被配置为向前移动活塞,以及可释放的保持装置(113),其构造成用于将活塞保持在初始位置,由此当所述保持装置被释放时,所述偏压装置被允许向前移动所述活塞以从所述储存器排出流体药物。